Cannabix Technologies Files
Contact-Free Breath Patent Application and Updates on Development
and Certification Plans
Cannabix has developed a contactless
alcohol breathalyzer for employers and vehicles.
Vancouver, British Columbia, Canada -- May 3, 2023 --
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE:
BLO) (OTC
PINK: BLOZF) (the "Company or Cannabix") developer of breath
testing devices for law enforcement and the workplace reports that
it has filed an International Patent Application ("PCT") titled,
"Contact-Free Breath Analysis Device and Method"
(PCT/CA2023/050409). This PCT application was the next step in
converting the Company's provisional patent filed in 2022 related
to contactless breath sampling technology. This PCT covers
new innovations and intellectual property related the development
to the detection of volatile organic compounds (VOCs) without the
use of mouthpiece or straws.
Development and Certification Plan for
Contactless Alcohol Breathalyzer ("CAB")
The Company has
developed its CAB technology for workplaces (a wall-mounted
version, see Figure 1) and an in-cabin vehicle version (Figure 2).
Cannabix commenced pilot testing of its workplace CAB with Montana
based Friedel, LLC ("Friedel Clinic") in March 2023 and the device
is preforming well with over 300 breath samples taken thus far. Due
to the encouraging usage results and unique market position of the
CAB device, Cannabix has begun efforts to build a commercial
workplace CAB unit for certification. The CAB device joins the
Company's portfolio of marijuana breath testing technologies under
development.
The Company has
received strong interest from the U.S. and Australia for
development and commercialization of a CAB wall mounted workplace
unit targeted for small to medium sized enterprises (SME's).
Alcohol is still the number one threat to workplace safety in the
U.S., however more workers are testing positive for marijuana than
ever before (1). An increasing number of employers are taking
proactive measures to safeguard their workers and their operations
by implementing alcohol testing procedures. Workplace testing
instances typically include random testing, reasonable cause
testing, pre-employment testing, pre-promotion testing,
post-incident testing, and return-to-work testing. The wall mounted
CAB would be targeted for all of the above testing instances, and
would be especially effective with pre-access alcohol testing before and during
work hours. Furthermore, the device could be used in bars,
restaurants and hotels and a whole host of other targeted locations
and organizations. Video of CAB can be seen at https://cannabixtechnologies.com/technology/contactless-alcohol-breathalyzer/
Figure 1. Wall Mounted Contactless
Alcohol Breathalyzer Prototype
The Company has
commenced discussions with electronics certification companies in
Canada and Germany to develop a certification plan and prepare for
standards testing (for alcohol devices). The Company is also
rapidly developing plans for this product for the United States and
Canadian markets.
CAB Features
Company engineers
have been developing a robust feature set for the CAB that includes
contactless and direct breath testing, photo identity confirmation,
time and attendance features. A live data management portal for
managers seeking real-time Blood Alcohol Content (BAC) results via
the text and email has been developed. This data management system
uses best in class Amazon Web
Services (AWS) for its cloud-based infrastructure and
security.
CAB Calibration, Sensor Array and
AI
Cannabix engineers
have developed a pre-calibrated modular cartridge that will allow
organizations to quickly and easily maintain their CAB devices.
Furthermore, it will allow for distributors of the CAB an efficient
way to support devices in the field. The wall mounted CAB would act
as a primary "touch point" for employees on a routine basis to
submit breath samples as they enter their place of work. Breath and
other information captured with the device will provide a rich set
of data to employers for occupational health, safety, personal and
human resource purposes. Cannabix engineers are also working on
ways to boost value by incorporating multiple sensory cartridges as
well as new AI algorithms to provide meaningful data to both users
and administrators, including adding sensors for
?9-tetrahydrocannabinol (THC).
Rav Mlait, CEO of
Cannabix stated, "We are very excited to move forward with
certification efforts for the Contactless Alcohol Breathalyzer. We
have moved our device development to a common technology platform
with similar chipsets, hardware components and software for both
marijuana and alcohol screening devices. This includes our handheld
Breath Collection Unit (BCU) for THC, THC Breath Analyzer (THCBA)
and Contactless Alcohol Breathalyzer (CAB). This strategy will
allow us to better scale and streamline our development.
Furthermore, our use of AI algorithms across this platform is
quickly broadening our capabilities."
Vehicle Alcohol Breath Screening
The Company
initially developed its CAB technology in response to interest in
new vehicle alcohol detection technologies. Recently on April
20, 2023 Mothers Against Drunk
Driving (MADD) highlighted a new report published in the
Journal of the American Medical
Association (JAMA) that shows strong public support for
equipping all new cars with impaired driving prevention technology,
as mandated in the 2021 Bipartisan Infrastructure Law (2). In
November 2021, the U.S. House of Representatives, passed the
Infrastructure Investment and Jobs Act (IIJA) which called for new
cars to come equipped with technology that will detect alcohol in
breath. The legislation directed the National Highway Traffic
Safety Administration to set new safety standards within three
years for impaired driving safety equipment on all new vehicles (3)
(4).
Cannabix Vehicle Contactless Alcohol
Breathalyzer
The Vehicle CAB
technology developed by Cannabix allows for a driver to direct a
breath sample towards a small orifice integrated into a device
behind the steering wheel for in-cabin vehicle use – in a
completely contactless manner. The CAB is fundamentally different
than existing alcohol breathalyzers and interlock systems that
require users to use a mouthpiece or straw and directly blow into a
handheld device that is connected to the vehicle usually with a
cable. The Cannabix CAB could be integrated into various locations
in the vehicle cabin. The CAB provides a warning, pass or fail
result along with a Blood Alcohol Content (BAC) level on the screen
for the driver to see. This kind of technology holds potential to
be integrated with interlock systems and be used in various
settings including automotive, heavy-duty equipment, heavy
transport vehicles, watercraft and motorbikes. The Company is
actively seeking a partner to advance this technology.
Readers are advised
that, although the Company has achieved proof of concept prototype
for the CAB, the testing method and device is still in the
preapproval stage and accordingly the Company is not currently
making any express or implied claims that the technology will
proceed to commercial use.
(1) https://ohsonline.com/Articles/2022/10/01/Alcohol-Is-Still.aspx?Page=1
(2) https://madd.org/press-release/new-jama/
(3) https://www.iihs.org/news/detail/alcohol-detection-systems-could-prevent-more-than-a-fourth-of-u-s-road-fatalities
(4) https://www.madd.org/press-release/auto-technology-that-stops-drunk-driving-now-required-by-law
About Cannabix
Technologies Inc.
Cannabix
Technologies Inc. is a developer of marijuana breathalyzer
technologies for law enforcement and the workplace. Cannabix is
working to develop drug-screening devices that will detect THC -
the psychoactive component of marijuana that causes impairment
using breath samples. Breath testing for THC would allow employers
and law enforcement to identify recent marijuana use that
better aligns with impairment. Cannabix devices are in the advanced
prototype and pre-clinical testing stage.
We seek Safe
Harbor.
On behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix
Technologies Inc.
For further
information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept
responsibility for the adequacy or accuracy of this
release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that
involves various risks and uncertainties regarding future events.
Such forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that its development of
breathalyzer technology will provide any benefit to the Company,
and no assurance that any proposed new products will be built, will
be successful in beta testing or clinical trials. The is no
assurance that the Company will enter into any partnerships to
advance any of its corporate initiatives or technologies. There is
no assurance that any "patent pending" or "provisional patents"
technologies licensed by the Company or owned by the Company will
receive patent status by regulatory authorities. The Company
is not currently selling commercial breathalyzers. Actual results
and future events could differ materially from those anticipated in
such information. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend to update these forward-looking
statements.
501-3292 Production Way, Burnaby,
B.C., V5A 4R4
Phone: (604)
551-7831
Fax: 604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com